Navigation Links
Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients

Patients who undergo lung transplants suffer from rejection of the organ. Hence according to a study researchers have found that inhaled anti-rejection drug, cyclosporine significantly reduces// rejection and results in better lung function. The study results were presented at the American Thoracic Society International Conference. The findings come from the same study that previously found that inhaled cyclosporine improved survival and extended periods of chronic rejection-free survival in lung transplant patients. Those results were published in The New England Journal of Medicine in January 2006. ‘Many lung transplant patients develop chronic rejection of the new lung—it is the Achilles heel of the transplant process,’ said lead researcher Aldo Iacono, M.D., Medical Director of Lung Transplantation at the University of Maryland in Baltimore.

‘Typically, patients experience a progressive, inexorable decline in lung function, most likely because of this chronic rejection and infections. This finding that aerosolized cyclosporine preserves lung function bolsters our previous findings that the drug reduces chronic rejection of the lung.’ The new study looked at 58 lung transplant patients, who were randomly assigned to inhale either 300 mg of aerosol cyclosporine or aerosol placebo three days a week for the first two years after their transplant. Both groups received oral anti-rejection medicines.

Patients who received the placebo experienced a decline in lung function that was four times as great as those who inhaled the cyclosporine. There was no difference in the rate of acute rejection of the lung (rejection occurring in the first few weeks after surgery) between the two groups. ‘Since the early 1990s we have been studying inhaled cyclosporine in lung transplant patients after they experience chronic rejection, but this is the first trial in which inhaled cyclosporine was used soon after the lung transplant occurred, before chronic rejection sets in,’ Dr. Iacono said. About 1,700 lung transplants are done at 150 centers around the world each year, but they are among the riskiest types of transplant surgery.

Almost half of recipients die within three years, and the long-term survival rate has not changed much in the last 20 years. Dr. Iacono said that the data on the drug's impact on survival and chronic rejection were presented to the U.S. Food and Drug Administration in June 2005, and that the FDA requested further studies. ‘I am hoping that the lung transplant community can work together to organize a multi-center trial," he said. "If we find promising results from a new, bigger, trial, and the drug becomes readily available, it could make a big difference for lung transplant patients.’

Source: Nwswise
'"/>




Related medicine news :

1. Inhaled Steroids Safe & Effective for Children with Asthma
2. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
3. The Effectiveness Of Inhaled Corticosteroids Studied
4. The Effectiveness Of Inhaled Corticosteroids Studied
5. Inhaled nitric oxide therapy does not reduce death risk of infants
6. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
7. HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy
8. Inhaled Insulin To Be Made Available in India
9. Inhaled Insulin Could Rock The Drug Market Soon
10. High Cost Forces NHS To Reject Inhaled Insulin
11. Inhaled Insulin: A New Modality for Management of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
Breaking Medicine Technology: